

NC MEDI-CAPS LIMITED

Regd. Office and works:

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231

Pithampur - 454775, Dist. Dhar

Madhya Pradesh, India

Ph:- 07292-256205

Fax:- 0731-4041435

E mail:- investors@medicaps.com

Website:- www.medicaps.com

MCL/SE/2021-2022

Date: 27.08.2021

Online filing at: www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street Fort, Mumbai - 400001 (M.H.)

Subject: Clarification Letter in respect of Discrepancy in Financial result for the Quarter Ended 30.06.2021.

Ref: Your mail dated 26th August, 2021 regarding Discrepancies in Consolidated Financial Results

Dear Sir/Madam,

With reference to the Subject captioned above, we received an email from your good office dated 26th August, 2021 for discrepancy observed in the Financial Results for the quarter ended 30.06.2021. It may please be noted that due to typographical error it was mentioned as Audited instead of unaudited, however the financial results filled are Un-Audited only in Consolidated Financial Results for the quarter ended 30.06.2021 and statutory auditors have also reviewed the financial result and given report on the basis of unaudited financial result only.


Further regarding calculation of EPS you may please note that earlier EPS was calculated by including comprehensive income also due to error in excel formula therefore EPS shown is positive instead of negative EPS. Now EPS has been restated without considering comprehensive Income.

Accordingly we hereby resubmit the updated standalone and consolidated unaudited financial statement along with limited review reports for quarter ended 30th June, 2021. Further we would also update the above financial statements in XBRL mode.

Kindly take the same in your record and oblige.

Thanking You,
Yours Faithfully,

For **MEDI-CAPS LIMITED**


ALOK K. GARG
MANAGING DIRECTOR
DIN: 00274321



Encl.: updated Unaudited Standalone and Consolidated Financial Results along with limited review reports;

*Corporate Office: 201, Pushpratna Paradise 9/5 New Palasiya,
Opposite VCO Bank Indore (M.P.) 452001
Contact No: 0731-4028148*

MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DISTT. DHAR (M.P.),



Tel: 07292-256205, Fax: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231


STATEMENT OF STANDALONE AND CONSOLIDATED UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2021

(Amount in Lacs except Shares & EPS)

Sr. No.	Particulars	Standalone				Consolidated			
		3 Months ended on 30.06.2021 (Unaudited)	3 Months ended on 31.03.2021 (Audited)	(P.Y.) 3 Months ended on 30.06.2020 (Unaudited)	Previous Year ended on 31.03.2021 (Audited)	3 Months ended on 30.06.2021 (Un-Audited)	3 Months ended on 31.03.2021 Audited)	(P.Y.) 3 Months ended on 30.06.2020 (Unaudited)	Previous Year ended on 31.03.2021 (Audited)
I	Income from operations								
	(a) Net sales	0.00	0.00	0.00	0.00	1717.94	1309.43	1202.82	5741.57
	(b) Other operating income	0.00	0.00	0.00	0.00	4.10	42.86	17.01	130.33
I	Total income from operation	0.00	0.00	0.00	0.00	1722.03	1352.28	1219.83	5871.89
II	Other Income	1.27	0.00	0.00	0.00	12.37	15.40	28.20	58.37
III	Total income (I+II)	1.27	0.00	0.00	0.00	1734.40	1367.68	1248.03	5930.26
IV	Expenses								
	a) Cost of material consumed	0.00	0.00	0.00	0.00	802.38	785.40	549.70	3107.60
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	58.60	-142.17	23.26	-171.32
	d) Employee benefits expense	4.13	0.00	0.00	0.00	164.38	188.23	132.87	670.99
	e) Finance costs	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	f) Power Cost	0.00	0.00	0.00	0.00	45.96	89.20	50.97	256.47
	g) Depreciation and amortisation expense	5.44	0.00	0.00	0.00	47.34	40.18	37.31	152.11
	h) Other expenses	4.02	0.00	0.00	0.00	287.75	176.45	215.75	790.43
	Total Expenses (IV)	13.58	0.00	0.00	0.00	1406.41	1137.29	1009.86	4806.28
V	Profit / (Loss) before exceptional item & tax (III-IV)	-12.32	0.00	0.00	0.00	327.99	230.39	238.17	1123.98
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit/ (Loss) before tax (V-VI)	-12.32	0.00	0.00	0.00	327.99	230.39	238.17	1123.98
VIII	Tax expense								
	a) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	b) Deferred Tax	0.00	-0.51	0.00	(0.51)	0.00	(0.51)	0.00	(0.51)
	Total Tax Expenses	0.00	-0.51	0.00	(0.51)	0.00	(0.51)	0.00	(0.51)


IX	Profit (Loss) for the period from continuing operations (VII-VIII)	-12.32	0.51	0.00	0.51	327.99	230.90	238.17	1124.49
X	Profit/(loss) from discontinued operations	6.83	29.91	(27.45)	(11.59)	6.83	29.91	-27.45	(11.59)
XI	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	6.83	29.91	(27.45)	(11.59)	6.83	29.91	(27.45)	(11.59)
XIII	Profit/(loss) for the period (IX+XII)	(5.49)	30.42	(27.45)	(11.08)	334.82	260.81	210.72	1112.90
XIV	Profit or Loss Attributable to owners of Parents	0.00	0.00	0.00	0.00	334.82	260.81	210.72	1112.90
XV	Profit or Loss Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XVI	Other comprehensive income								
	(a) (i) items that will not be reclassified to statement of profit & loss	26.09	17.88	33.17	123.47	65.33	40.93	73.10	262.88
	(ii) Income tax on items that will not to be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Other comprehensive income :	26.09	17.88	33.17	123.47	65.33	40.93	73.10	262.88
XVII	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	20.60	48.30	5.72	112.39	400.15	301.74	283.82	1375.78
XVIII	Paid-up equity share capital of the company (Face value Rs.10/- Per Share)	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
XIX	Reserves excluding revaluation reserves	0.00	0.00	0.00	4849.91	0.00	0.00	0.00	9224.24
XX	Earnings per equity share (for continuing operation)								
	a) Basic	-0.10	0.15	0.05	0.99	2.63	2.18	2.28	11.13
	a) Diluted	-0.10	0.15	0.05	0.99	2.63	2.18	2.28	11.13
XXI	Earnings per equity share (for discontinued operation)								
	a) Basic	0.05	0.24	0.00	(0.09)	0.05	0.24	0.05	(0.09)
	a) Diluted	0.05	0.24	0.00	(0.09)	0.05	0.24	0.05	(0.09)



XXII	Earnings per equity share (for discontinued and continuing operation)								
	a) Basic	-0.05	0.39	0.05	0.90	2.68	2.42	2.32	11.04
	a) Diluted	-0.05	0.39	0.05	0.90	2.68	2.42	2.32	11.04

Date: 12.08.2021
Place: INDORE

For, MEDICAPS LIMITED


ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321



Consolidated Segmentwise Revenue, Results and Capital Employed for Quarter ended 30th June, 2021

(Amount in Lakhs)



S.No.	Segment Revenue	Quarter Ended		Year Ended	
		30th June, 2021	31st March, 2021	30th June, 2020	31st March, 2021
		Unaudited	Audited	Unaudited	Audited
1	Segment Revenue				
	Pharma Division	1,733.13	1,367.68	0.00	5,930.26
	Real Estate Division	1.27	0.00	0.00	0.00
	Other	0.00	0.00	0.00	0.00
	Gross Turnover	1,734.40	1,367.68	0.00	5,930.26
2	Segment Results				
	Pharma Division	340.31	230.39	0.00	1,123.98
	Real Estate Division	(12.32)	0.00	0.00	0.00
	Other	0.00	0.00	0.00	0.00
	Total Segment Profit Before Interest & Tax	327.99	230.39	0.00	1,123.98
	Interest Income	0.00	0.00	0.00	0.00
	Interest Expenses	0.00	0.00	0.00	0.00
	Other Unallocable Income net of Expenditure	0.00	0.00	0.00	0.00
	Profit Before Tax	327.99	230.39	0.00	1,123.98
3	Capital Employed				
	Segment Assets (A)				
	Pharma Division	11,695.98	11,381.88	0.00	11,381.88
	Real Estate Division	100.00	100.00	0.00	100.00
	Other	0.00	0.00	0.00	0.00
	Total (A)	11,795.98	11,481.88	0.00	11,481.88

[Handwritten Signature]



Segment Liabilities (B)					
	Pharma Division	824.60	910.64	0.00	910.64
	Real Estate Division	100.00	100.00	0.00	100.00
	Other	0.00	0.00	0.00	0.00
	Total (B)	924.60	1,010.64	0.00	1,010.64
4 Total Capital Employed (Segment Assets-Segment Liabilities)					
	Pharma Division	10,871.38	10,471.24	0.00	10,471.24
	Real Estate Division	0.00	0.00	0.00	0.00
	Other	0.00	0.00	0.00	0.00
	Total Capital Employed (Segment Assets-Segment Liabilities)	10,871.38	10,471.24	0.00	10,471.24


Notes : It may please be noted that segment reporting has started in the company from the quarter ended 30th September, 2020, and in light of the same the details for the corresponding quarter is NIL.

1. The above unaudited results for the Quarter ended June 30, 2021 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on August 12, 2021. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have expressed an unmodified opinion. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
3. The above consolidated results included the result of wholly owned subsidiary company i.e. Medgel Private Limited.
4. The Company has two reportable segment for the Consolidated Financial Statements which consists Pharma division and Real Estate division in accordance with Ind AS-108 Operating Segment.
5. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
6. The aforesaid Un-audited financial Results will be uploaded on the Company's website www.medicaps.com and will also be available on the websites of the Stock exchange i.e. www.bseindia.com for the benefit of shareholders and investors.
7. The figures for the quarter ended March 31, 2021 are the balancing figures between the audited figures in respect of the full financial year and the years to date figures up to the third quarter which were subjected to limited review.
8. The Company has taken into account the possible impact of known events arising out of COVID 19 pandemic in the preparation of financial results. The Company will continue to monitor for any material changes to future economic conditions.
9. On 21st Nov., 2019, the company announced to permanently discontinue Company's operations related to production/manufacturing of Hard Gelatin Capsule Shell. The discontinuation is consistent with the Company's long-term strategy to focus its activities in the areas of Real Estate Business and to divest unrelated activities. From this quarter income/expenses relating to real estate project has been shown in continuing operation and details relating to discontinued operation has been shown separately.
10. Description of Income & Expenditure of Discontinue operations

	Particulars	(Amount In Lakhs)	
		3 Month Ended 30.06.2021	3 Months Ended 31.03.2021
I	Income from operations	0	0
II	Other Income	11.12	61.30
III	Total income (I+II)	11.12	61.30


[Handwritten Signature]



IV	Expenses		
	a) Changes in Inventories of finished goods, & work in progress		
	b) Employee benefits expense	0.00	0.00
	c) Finance Cost	0.00	3.84
	d) Depreciation expense	0.00	0.03
	e) Other expenses	2.84	5.94
	Total Expenses (IV)	1.45	21.59
V	Net Profit / Loss From Discontinue Operation	4.29	31.39
		6.83	29.91

Date: 12.08.2021
Place: INDORE

For, MEDICAPS LIMITED



ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

